<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="correction" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Drug Saf. Regul.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Drug Safety and Regulation</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Drug Saf. Regul.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2674-0869</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1729828</article-id>
<article-id pub-id-type="doi">10.3389/fdsfr.2025.1729828</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Correction</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Correction: Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings</article-title>
<alt-title alt-title-type="left-running-head">Gavin et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fdsfr.2025.1729828">10.3389/fdsfr.2025.1729828</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gavin</surname>
<given-names>Kathleen M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/539255"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sundermann</surname>
<given-names>Matthew L.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3208549"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wieland</surname>
<given-names>Alethea</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3088655"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Datavant</institution>, <city>Phoenix</city>, <state>AZ</state>, <country country="US">United States</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Advarra</institution>, <city>Columbia</city>, <state>MD</state>, <country country="US">United States</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Kathleen M. Gavin, <email xlink:href="kathleen@datavant.com">kathleen@datavant.com</email>
</corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-11-07">
<day>07</day>
<month>11</month>
<year>2025</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>5</volume>
<elocation-id>1729828</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>10</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>10</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Gavin, Sundermann and Wieland.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Gavin, Sundermann and Wieland</copyright-holder>
<license>
<ali:license_ref start_date="2025-11-07">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front. Drug Saf. Regul." journal-id-type="nlm-ta" xlink:href="10.3389/fdsfr.2025.1626822" ext-link-type="doi">A Correction on <article-title>Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings</article-title> by Gavin KM, Sundermann ML and Wieland A (2025). Front. Drug Saf. Regul. 5:1626822. doi: <object-id>10.3389/fdsfr.2025.1626822</object-id>
</related-article>
<kwd-group>
<kwd>real world data</kwd>
<kwd>safety surveillance</kwd>
<kwd>pharmacovigilance</kwd>
<kwd>risk management</kwd>
<kwd>privacy preserving record linkage (PPRL)</kwd>
<kwd>tokenization</kwd>
<kwd>data linkage</kwd>
<kwd>federated data sharing</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Advanced Methods in Pharmacovigilance and Pharmacoepidemiology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>The reference for [EMA, 2017] was erroneously written as &#x201c;EMA (2017). Guideline on good pharmacovigilance practices (GVP) module IX&#x2013;Signal management. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf</ext-link>.&#x201d; It should be &#x201c;European Medicines Agency (2017). Guideline on good pharmacovigilance practices (GVP) module IX&#x2013;Signal management. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf</ext-link>&#x201d;.</p>
<p>The reference for European Medicines Society, 2023 was erroneously written as &#x201c;European Medicines Society (2023). ICH M14 general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines - scientific guideline. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-scientific-guideline">https://www.ema.europa.eu/en/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-scientific-guideline</ext-link>&#x201d;. It should be &#x201c;European Medicines Agency (2025). ICH M14 general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines - scientific guideline. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-scientific-guideline">https://www.ema.europa.eu/en/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-scientific-guideline</ext-link>&#x201d;.</p>
<p>The reference for European Medicines Society, 2025 was erroneously written as &#x201c;European Medicines Society (2025). Data analysis and real world interrogation network (DARWIN EU). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu">https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu</ext-link>&#x201d;. It should be &#x201c;European Medicines Agency (2025). Data analysis and real world interrogation network (DARWIN EU). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu">https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu</ext-link>&#x201d;.</p>
<p>The reference for Rosati et al., 2022 was erroneously written as &#x201c;Rosati, K., Jorgensen, N., Soliz, M., and Evans, B. (2022). HIPAA and common rule compliance in the Sentinel initiative. Sentinel initiative principles and policies&#x201d;. It should be &#x201c;Rosati, K., Jorgensen, N., Soliz, M., and Evans, B. (2018). HIPAA and common rule compliance in the Sentinel initiative. Sentinel initiative principles and policies. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.sentinelinitiative.org/sites/default/files/communications/publications-presentations/HIPAA-Common-Rule-Compliance-in-Sentinel-Initiative.pdf">https://www.sentinelinitiative.org/sites/default/files/communications/publications-presentations/HIPAA-Common-Rule-Compliance-in-Sentinel-Initiative.pdf</ext-link>&#x201d;.</p>
<p>The reference for U.S. Food and Drug Administration, 2023a was erroneously written as &#x201c;U.S. Food and Drug Administration (2023a). Data standards for drug and biological product submissions containing real-world data guidance document. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug</ext-link>&#x201d;. It should be &#x201c;U.S. Food and Drug Administration (2023a). Data standards for drug and biological product submissions containing real-world data guidance document. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data</ext-link>&#x201d;.</p>
<p>The original article has been updated.</p>
</body>
<back>
<sec sec-type="disclaimer" id="s1">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Approved by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1261749/overview">Frontiers Editorial Office</ext-link>, Frontiers Media SA, Switzerland</p>
</fn>
</fn-group>
</back>
</article>